Weng et al. 2022 (PRJNA871214)
General Details
| Title | The m6A Reader IGF2BP2 Regulates Glutamine Metabolism and Represents a Therapeutic Target in Acute Myeloid Leukemia [Ribo-seq] |
|---|---|
| Organism | |
| Number of Samples | 6 |
| Release Date | 2022/08/19 00:00 |
| Sequencing Types | |
| Protocol Details |
Study Links
| GWIPS-viz | Trips-Viz |
|---|---|
Repository Details
| SRA | SRP393125 |
|---|---|
| ENA | SRP393125 |
| GEO | GSE211618 |
| BioProject | PRJNA871214 |
Publication
| Title | |
|---|---|
| Authors | Weng H,Huang F,Yu Z,Chen Z,Prince E,Kang Y,Zhou K,Li W,Hu J,Fu C,Aziz T,Li H,Li J,Yang Y,Han L,Zhang S,Ma Y,Sun M,Wu H,Zhang Z,Wunderlich M,Robinson S,Braas D,Hoeve JT,Zhang B,Marcucci G,Mulloy JC,Zhou K,Tao HF,Deng X,Horne D,Wei M,Huang H,Chen J |
| Journal | Cancer cell |
| Publication Date | 2022 Dec 12 |
| Abstract | N 6 -Methyladenosine (m 6 A) modification and its modulators play critical roles and show promise as therapeutic targets in human cancers, including acute myeloid leukemia (AML). IGF2BP2 was recently reported as an m 6 A binding protein that enhances mRNA stability and translation. However, its function in AML remains largely elusive. Here we report the oncogenic role and the therapeutic targeting of IGF2BP2 in AML. High expression of IGF2BP2 is observed in AML and associates with unfavorable prognosis. IGF2BP2 promotes AML development and self-renewal of leukemia stem/initiation cells by regulating expression of critical targets (e.g., MYC, GPT2, and SLC1A5) in the glutamine metabolism pathways in an m 6 A-dependent manner. Inhibiting IGF2BP2 with our recently identified small-molecule compound (CWI1-2) shows promising anti-leukemia effects in vitro and in vivo. Collectively, our results reveal a role of IGF2BP2 and m 6 A modification in amino acid metabolism and highlight the potential of targeting IGF2BP2 as a promising therapeutic strategy in AML. Copyright © 2022 Elsevier Inc. All rights reserved. |
| PMC | PMC9772162 |
| PMID | 36306790 |
| DOI |
| Run Accession | Study Accession | Scientific Name | Cell Line | Library Type | Treatment | GWIPS-viz | Trips-Viz | Reads | BAM | BigWig (F) | BigWig (R) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRR21146250 | PRJNA871214 | Homo sapiens | MonoMac6Human acute myeloid leukemia (AML) cells |  |
 |
 |
 |
|
|
||||
| SRR21146249 | PRJNA871214 | Homo sapiens | MonoMac6Human acute myeloid leukemia (AML) cells | |
|
|
|
|
|
||||
| SRR21146248 | PRJNA871214 | Homo sapiens | MonoMac6Human acute myeloid leukemia (AML) cells | |
|
|
|
|
|
||||
| SRR21146247 | PRJNA871214 | Homo sapiens | MonoMac6Human acute myeloid leukemia (AML) cells | |
|
|
|
|
|
||||
| SRR21146246 | PRJNA871214 | Homo sapiens | MonoMac6Human acute myeloid leukemia (AML) cells | |
|
|
|
|
|
||||
| SRR21146245 | PRJNA871214 | Homo sapiens | MonoMac6Human acute myeloid leukemia (AML) cells | |
|
|
|
|
|
||||
| Run Accession | Study Accession | Scientific Name | Cell Line | Library Type | Treatment | GWIPS-viz | Trips-Viz | Reads | BAM | BigWig (F) | BigWig (R) |
ⓘ For more Information on the columns shown here see: About